Mechanistic Evaluation of Guanfacine on Drinking Behavior
Conditions
Mental Health & Behavioral Research
Phase COVID-II
Volunteers
Health Professionals
What is the purpose of this trial?
In this study, we are seeking individuals who are interested in reducing or cutting back their drinking behavior. We will be looking at how the medication Intuniv, which is Guanfacine, influences drinking behavior. Guanfacine is a medication that has been approved by the Food and Drug Administration (FDA) to treat high blood pressure and ADHD. There are three phases to the study.
- Ages21 years - 70 years
- GenderBoth
- Trial withNational Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Start Date03/01/2019
- End Date09/29/2026
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Last Updated07/15/2021
- Study HIC#2000023970